MARKET

IMGN

IMGN

ImmunoGen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.880
+0.130
+2.74%
After Hours: 4.900 +0.02 +0.41% 19:40 07/02 EDT
OPEN
4.780
PREV CLOSE
4.750
HIGH
4.960
LOW
4.720
VOLUME
2.05M
TURNOVER
--
52 WEEK HIGH
7.07
52 WEEK LOW
1.950
MARKET CAP
851.10M
P/E (TTM)
-8.3892
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average IMGN stock price target is 7.04 with a high estimate of 12.00 and a low estimate of 4.000.

EPS

IMGN News

More
Hedge Funds Have Never Been This Bullish On ImmunoGen, Inc. (IMGN)
Insider Monkey · 06/24 02:42
ImmunoGen Presents Preclinical Data On IMGN151 At Virtual AACR Annual Meeting
ImmunoGen Presents Preclinical Data on IMGN151 at Virtual AACR Annual Meeting ImmunoGen Presents Preclinical Data on IMGN151 at Virtual AACR Annual Meeting Next Generation FRα-Targeting ADC Engineered to Maximize
Benzinga · 06/22 13:14
ImmunoGen Presents Preclinical Data on IMGN151 at Virtual AACR Annual Meeting
ImmunoGen Presents Preclinical Data on IMGN151 at Virtual AACR Annual Meeting
Business Wire · 06/22 13:01
ImmunoGen Announces Virtual 2020 Annual Meeting of Shareholders
Business Wire · 06/03 13:00
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · 06/02 13:00
ImmunoGen Appoints Stacy Coen as Senior Vice President and Chief Business Officer
Business Wire · 06/01 13:00
Why Is ImmunoGen (IMGN) Up 14.7% Since Last Earnings Report?
Zacks · 05/31 16:30
ImmunoGen Presents Initial Data at ASCO from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status
Business Wire · 05/29 13:01

Industry

Biotechnology & Medical Research
+0.67%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About IMGN

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.
More

Webull offers kinds of ImmunoGen, Inc. stock information, including NASDAQ:IMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMGN stock methods without spending real money on the virtual paper trading platform.